drugset / Trial / NCT00004885

Fluorouracil and Leucovorin With or Without Irinotecan in Treating Patients With Metastatic Colorectal Cancer

NCT00004885 ↗

RandomizedTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether fluorouracil and leucovorin plus irinotecan is more effective than fluorouracil and leucovorin alone for colorectal cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of fluorouracil and leucovorin with or without irinotecan in treating patients who have metastatic colorectal cancer.

Timeline

Start
1999-07
Primary completion
2001-07
Completion
—

Outcome

Met primary endpoint

paper compared with 6.4 months (95% CI, 5.3 to 7.2 months) in the AIO arm (P < .0001). PMID 15939923 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Irinotecan Small molecule 80 mg/m2 Intravenous
Subject Leucovorin Small molecule 500 mg/m2 Intravenous
Subject fluorouracil Small molecule 2 g —
Subject fluorouracil Small molecule 2.3 g —
Subject fluorouracil Small molecule 2.6 g —

Indications